Form 4: GlucoTrack Director Ballantyne Acquires Shares and Exercises Warrants
SEC Form 4 Filing
Director John Ballantyne reports acquisition of shares and cashless exercise of warrants in GlucoTrack, Inc.
Summary
- John Ballantyne, a director and 10% owner of GlucoTrack, Inc., reported several transactions involving the company's common stock and warrants.
- On July 30, 2024, Ballantyne's Rev Trust entered into a convertible promissory note and warrant agreements with GlucoTrack for a $4,000,000 private placement.
- On November 14, 2024, the Ballantyne Trust converted approximately $4,093,112 of debt into 132,036 shares of common stock, along with Series A and Series B common warrants, at a conversion price of $31.00 per share.
- On March 12, 2025, the Ballantyne Trust exercised Series B Common Warrants on a cashless basis, receiving 2,560,553 shares of common stock.
- The transactions reflect both direct and indirect ownership through the John A. Ballantyne Rev Trust 08/01/2017.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of previously agreed-upon arrangements. The cashless warrant exercise is dilutive but provides capital.
Positives
- The conversion of debt into equity could be seen as a positive sign of confidence in the company's future.
- The cashless exercise of warrants provides the company with additional capital without immediate cash outlay from the warrant holder.
Risks
- The cashless exercise of warrants dilutes existing shareholders' equity.
- The conversion of debt could indicate a need for financing.
Industry Context
Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates the actions of a major shareholder and director.
Related Party Transactions
- The transactions involve the John A. Ballantyne Rev Trust, a related party due to John A. Ballantyne's role as trustee and director of GlucoTrack.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares from the cashless warrant exercise.
- The company's capital structure is affected by the debt conversion and warrant exercises.
Key Dates
| Date | Description |
|---|---|
| 07/30/2024 | Issuer entered into a convertible promissory note and three warrant agreements with the John A. Ballantyne Rev Trust 08/01/2017. |
| 08/01/2017 | Date of the John A. Ballantyne Rev Trust. |
| 11/12/2024 | The day prior to the date the securities purchase agreement governing the Conversion was executed. |
| 11/14/2024 | Issuer completed a public offering and the Ballantyne Trust agreed to convert debt into shares and warrants. |
| 01/03/2025 | Series A and B Common Warrants first exercisable date. |
| 02/25/2025 | A 1-for-20 reverse stock split of the Common Stock was implemented. |
| 03/12/2025 | The Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants. |
| 03/26/2025 | Transaction date for acquisition of 4,126 shares. |
| 03/31/2025 | Date of signature for the Form 4 filing. |
| 07/03/2027 | Series B Common Warrants expiration date. |
| 01/03/2030 | Series A Common Warrants expiration date. |
| 07/30/2034 | Warrants to Purchase Common Stock expiration date. |
Keywords
GlucoTrack, Ballantyne, warrants, common stock, debt conversion, cashless exercise, Form 4, director, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.